HUNT VALLEY, Md.--(BUSINESS WIRE)--CepTor Corporation (OTC BB:CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that its Investigational New Drug application (IND) for Myodur to be used in Duchenne muscular dystrophy trials remains on hold. In a teleconference with the FDA, the agency reported that there are two remaining issues that it would like the Company to address before moving into human trials. The Company reported that the remaining two items are straightforward and addressable.
